Deficit of glucocorticoid-induced leucine zipper amplifies angiotensin-induced cardiomyocyte hypertrophy and diastolic dysfunction

Donato Cappetta1 | Antonella De Angelis1 | Sara Flamini2 | Anna Cozzolino1 | Oxana Bereshchenko3 | Simona Ronchetti2 | Eleonora Cianflone4 | Andrea Gagliardi2 | Erika Ricci2 | Concetta Rafaniello1 | Francesco Rossi1 | Carlo Riccardi2 | Liberato Berrino1 | Stefano Bruscoli2 | Konrad Urbanek1,5

1Department of Experimental Medicine, University of Campania ‘Luigi Vanvitelli’, Naples, Italy
2Department of Medicine, Section of Pharmacology, University of Perugia, Perugia, Italy
3Department of Philosophy, Social Sciences and Education, University of Perugia, Perugia, Italy
4Department of Medical and Surgical Sciences, University ‘Magna Graecia’ of Catanzaro, Catanzaro, Italy
5Department of Experimental and Clinical Medicine, University ‘Magna Graecia’ of Catanzaro, Catanzaro, Italy

Correspondence
Antonella De Angelis, Department of Experimental Medicine, Section of Pharmacology, University of Campania ‘Luigi Vanvitelli’, Via Costantinopoli 16, 80138 Naples, Italy.
Email: antonella.deangelis@unicampania.it

Funding information
Ministero dell’Istruzione, dell’Università e della Ricerca, Grant/Award Number: PON03PE_00060_7, PRIN 2015-2015EASE8Z and PRIN 2017-2017XZMBYX

Abstract
Poor prognosis in heart failure and the lack of real breakthrough strategies validate targeting myocardial remodelling and the intracellular signalling involved in this process. So far, there are no effective strategies to counteract hypertrophy, an independent predictor of heart failure progression and death. Glucocorticoid-induced leucine zipper (GILZ) is involved in inflammatory signalling, but its role in cardiac biology is unknown. Using GILZ-knockout (KO) mice and an experimental model of hypertrophy and diastolic dysfunction, we addressed the role of GILZ in adverse myocardial remodelling. Infusion of angiotensin II (Ang II) resulted in myocardial dysfunction, inflammation, apoptosis, fibrosis, capillary rarefaction and hypertrophy. Interestingly, GILZ-KO showed more evident diastolic dysfunction and aggravated hypertrophic response compared with WT after Ang II administration. Both cardiomyocyte and left ventricular hypertrophy were more pronounced in GILZ-KO mice. On the other hand, Ang II-induced inflammatory and fibrotic phenomena, cell death and reduction in microvascular density, remained invariant between the WT and KO groups. The analysis of regulators of hypertrophic response, GATA4 and FoxP3, demonstrated an up-regulation in WT mice infused with Ang II; conversely, such an increase did not occur in GILZ-KO hearts. These data on myocardial response to Ang II in mice lacking GILZ indicate that this protein is a new element that can be mechanistically involved in cardiovascular pathology.

Keywords
angiotensin II, diastolic dysfunction, glucocorticoid-induced leucine zipper, glucocorticoids, myocardial hypertrophy

Donato Cappetta, Antonella De Angelis, Stefano Bruscoli, and Konrad Urbanek contributed equally to this work.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
1 | INTRODUCTION

The increasing recognition of the heterogeneity of heart failure (HF) phenotypes emphasizes the need of further elucidation of underlying mechanisms. Half of the patients with HF symptoms have normal systolic function, and the prevalence of this form of HF is on the rise at a rate of 1% per year. The growing number of HF patients is paralleled with the mounting burden of lifestyle-related co-morbidities, such as hypertension, obesity and diabetes.1,2 These chronic pathologies share low-grade chronic inflammation as a common denominator that, according to the current paradigm, drives the development of diastolic dysfunction and the progression towards HF.3,4

Glucocorticoids (GCs), the most powerful anti-inflammatory and immunosuppressive drugs available, are commonly used to treat chronic inflammatory and autoimmune diseases.5 GCs regulate numerous cellular functions in the cardiovascular system, such as cell growth, apoptosis, inflammation and regulation of vascular tone.5 Several studies have revealed a potential benefit of modulation of GC receptors in cardiovascular diseases.6 However, GCs have significant dose-dependent toxicity and reducing GC dosing has become a major theme of basic and clinical research. Several studies have reported a key role for glucocorticoid-induced leucine zipper (GILZ) in mediating the physiological and therapeutic effects of GCs.8-10 GILZ, whose expression is mainly regulated by GCs, is able to modulate cell proliferation, survival (mainly apoptosis) and differentiation.11-14 So far, GILZ involvement has been described in the modulation of the same immune and inflammatory responses implicated in GC-induced immunomodulation.11 Indeed, GILZ mediates thymocyte survival,12 inhibition of nuclear factor-xB (NF-xB) transcriptional activity,15,16 inhibition of ERK-1/2 activation and of Ras-dependent cell proliferation and oncogenic transformation.17 GILZ expression is not restricted to lymphoid cells, and it has been shown to play regulatory roles in adipocytes, osteoblasts and tubular renal cells.18-20 GILZ is also expressed in skeletal muscle tissue,21 where it is involved in the regulation of myogenesis and mediates GC-induced anti-myogenic activity.22 Apart the contribution to maturational programme in foetal cardiomyocytes, the role and relevance of GILZ to cardiovascular homeostasis and myocardial remodelling are unknown.23,24 For these reasons, we investigated the involvement of GILZ in the development of myocardial dysfunction, using a GILZ-knockout (KO) mouse and a model of left ventricular (LV) hypertrophy, fibrosis and diastolic dysfunction that develop following the infusion of angiotensin II (Ang II).

2 | MATERIALS AND METHODS

2.1 | Animals

All in vivo experiments were carried out in accordance with the National Ethical Guidelines (Italian Ministry of Health; DL vo 26, 4 March 2014) and the guidelines from Directive 2010/63/EU of the European Parliament. The animals were housed in the animal facilities of the University of Perugia in a controlled environment and provided with standard rodent chow and water ad libitum. Mice bearing a floxed GILZ allele were generated and maintained on a C57Bl/6 background as previously described.25 GILZ-KO mice were obtained by crossing mice bearing GILZ flox alleles with transgenic mice bearing the CMV-CRE transgene, resulting in the deletion of GILZ in all the cells of the body.26

2.2 | Experimental protocol

C57BL/6J mice were anaesthetized with 1.5% isoflurane and fitted subcutaneously beneath the scapula with a micro-osmotic pump (ALZET, Model 1002; Durect) containing Ang II (1.5 mg/kg/d). Control mice underwent the same surgical procedure but without mini-pump implantation. Mice were killed after 14 days of Ang II treatment. Hearts were excised and dissected, with one part being processed for histology and another snap-frozen in liquid nitrogen for molecular analysis. Spleen was collected for the analysis of inflammatory cytokines (Figure 1A). Our protocol was based on the studies that reported that Ang II, infused for 14 days in doses comparable to that used in our work, stimulates LV hypertrophy and remodelling, along with mild cardiac dysfunction.27-30

2.3 | Blood pressure and echocardiography

After 14 days of Ang II infusion, non-invasive measurement of blood pressure (tail cuff) was performed in conscious mice (BP-2000; Visitech Systems). In addition, mice under anaesthesia with 1.5% isoflurane underwent transthoracic echocardiography (Vevo 770; VisualSonics). As indices of systolic function, ejection fraction and fractional shortening were calculated from the internal LV diameters in short-axis view. Posterior wall thickness was also measured.31,32 LV filling pressure estimation was assessed by transmural pulsed-wave Doppler echocardiography in the four-chamber view. To assess diastolic function, mitral valve early wave peak (E wave), atrial wave peak (A wave), E/A ratio, isovolumetric relaxation time and E-wave deceleration time were measured.33 Heart rate was recorded during blood pressure and echocardiographic monitoring.

2.4 | Sample preparation and histological analysis

To prepare frozen sections, hearts were dissected and embedded in OCT compound (Thermo Fischer Scientific). Then, the tissue block was frozen in liquid nitrogen and stored at −80°C. Tissue sections (10 µm thick) were cut on a cryostat (CM3050 S; Leica Microsystems). For molecular biology analysis, samples were directly frozen in liquid nitrogen and stored at −80°C. Immunolabelling of GILZ (eBioscience), laminin (Sigma-Aldrich) and FoxP3 (Thermo Fischer Scientific) was performed. Immune cells were detected by CD45 and CD3 (BD PharMingen). Myocardial fibrosis was evaluated by collagen I (Novus
Biologicals) and vimentin (Abcam) stainings. Capillaries were visualized with FITC-conjugated isolectin B4 (Vector Laboratories). Cross-sectional microvessel profiles were counted in at least 10 fields and capillary density reported per mm$^2$. Apoptotic cells were detected by terminal deoxynucleotidyl transferase–mediated UTP end labelling (TUNEL) staining using an apoptosis detection kit (Takara) according to manufacturer’s instruction. Apoptotic cells were counted throughout the tissue section, and apoptotic rate was expressed per mm$^2$. Myocytes were demonstrated by α-sarcomeric actin (Sigma-Aldrich). FITC- and TRITC-conjugated secondary antibodies (Jackson ImmunoResearch) were used. Nuclei were counterstained with DAPI (Sigma-Aldrich). Sections were analysed with confocal microscope (LSM700; Zeiss). Myocyte cross-sectional area was measured using ImagePro Plus software (Media Cybernetics), and cell size distribution was calculated.  

2.5 | Real-time quantitative PCR

Total RNA was extracted from the heart and spleen tissue using the RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions. Conversion of total RNA to cDNA was performed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). All real-time PCRs were performed using the 7300 Real-Time PCR System (Applied Biosystem), and the amplifications were done using the TaqMan Gene Expression Master Mix (Applied Biosystems). GAPDH or β-tubulin was used as an endogenous control to normalize the variability in expression levels, and results were expressed as fold increase. The qPCR TaqMan probes (Applied Biosystems) were as follows: GILZ (Tsc22d3): Mm00726417_m1; FoxP3: Mm00475162_m1; IFN-γ: Mm01168134_m1; IL-1β: Mm00434228_m1; TNF-α: Mm00443258_m1; TGF-β: Mm01178820_m1; GATA4: Mm00484689_m1; CTGF: Mm01192933_g1; and Bax: Mm0043205. Quantitative analysis of expression of L-GILZ transcript isoform was performed using SYBR Green Gene Expression Master Mix (Applied Biosystems). Specific primers to identify L-GILZ were the following: For: ACCGCAACATAGACCAGACC; Rev: CACAGCGTACATCAGGTGGT.

2.6 | Western Blot

Protein extracts were obtained using RIPA buffer supplemented with protease (Sigma-Aldrich) and phosphatase (Thermo Fisher Scientific) inhibitor cocktails. Western blot analyses were performed using antibody against total NF-κB, phospho-NF-κB at serine 536 (phospho-NF-κBSer536; Cell Signaling Technology), Caspase-1 (Santa Cruz Biotechnology) and lamin B1 (nuclear loading control; Abcam), as previously described.  

2.7 | Statistics

Echocardiographic and blood pressure data were expressed as mean ± standard deviation; PCR and Western blot results were expressed as mean ± standard error of the mean. Multiple comparisons
were tested by one-way ANOVA and Bonferroni’s post-test. Data analysis was performed using GraphPad Prism 4. P-values were two-sided and considered statistically significant if $P < .05$.

3 | RESULTS

3.1 | GILZ expression in the heart

Hearts of GILZ-KO mice lacked the transcript at the baseline and upon Ang II exposure. The up-regulation of GILZ mRNA was detected in the myocardium of Ang II–infused WT mice, suggesting the involvement of this protein in the response to Ang II (Figure 1B). In addition, immunolocalization of GILZ in Ang II–exposed myocardium of WT animals showed the up-regulation of GILZ at protein level (Figure 1C). Interestingly, also the L-GILZ isoform expression, present in the heart of WT mice, was up-regulated after Ang II exposure (Figure 1D).

3.2 | Blood pressure and heart function

Infusion of Ang II resulted in a significant increase in blood pressure, with almost identical rise of mean pressure values in WT and GILZ-KO mice (Figure 2A). In conscious animals, heart rate of WT (491 ± 79) and KO (499 ± 69) did not statistically change after Ang II (480 ± 78 and 492 ± 93, in WT + Ang and KO + Ang, respectively). The mice did not show symptoms of lung congestion, and systolic function was normal across experimental groups (Figure 2B). Conversely, diastolic function resulted compromised after infusion of Ang II. Notably, genetic ablation of GILZ influenced on the degree of diastolic dysfunction of the myocardium after Ang

---

**FIGURE 2** The lack of GILZ partly aggravated diastolic function after Ang II. A, Rise in mean blood pressure upon Ang II did not present any statistical difference between WT and KO mice. B, Unchanged ejection fraction and fractional shortening demonstrated unimpaired systolic function. C, Evidence of diastolic dysfunction upon infusion of Ang II; KO + Ang mice showed a higher increment of E-wave deceleration time. *$P < .05$ vs strain-matched control; °$P < .05$ vs WT + Ang
II infusion. The decline of diastolic function indicated by the abnormal transmitral flow was markedly more profound in GILZ-KO mice, as evident by the significant increase in E-wave deceleration time (Figure 2C). Heart rate recorded in anaesthetized mice during echocardiography was comparable among groups (442 ± 30 in WT; 449 ± 59 in WT + Ang; 453 ± 27 in KO; 447 ± 34 in KO + Ang).

**Figure 3** Increment of LV hypertrophy after Ang II treatment was more marked in KO animals. A, Posterior wall thickness (normalized for bodyweight) elevation was more striking in GILZ-KO mice. B, Cardiomyocyte cross-sectional area demonstrated by laminin immunostaining (green). C, Frequency distribution curve of myocyte cross-sectional area was shifted rightwards in KO + Ang group in comparison with WT + Ang. D, FoxP3 transcript up-regulation upon Ang II was less marked in GILZ-KO hearts. E, Representative immunofluorescent images showing higher expression of FoxP3 (green) in the LV after exposure to Ang II. F, Up-regulation of GATA4 only occurred in WT + Ang hearts. Real-time quantitative PCR analysis of FoxP3 and GATA4 derived from 2 independent experiments and were presented relative to the expression of GAPDH mRNA. Graphs were expressed as mean ± standard error of the mean. G, Capillary rarefaction after Ang II in WT and KO hearts. H, Representative images showing lower capillary density in WT + Ang and KO + Ang mice compared with untreated animals. Endothelial cells were detected by isolecitin B4 (green). Nuclei in (E, H) were counterstained with DAPI (blue). *P < .05 vs strain-matched control; °P < .05 vs WT + Ang. Scale bars: (B) 50 µm, (E) 25 µm, (H) 20 µm.
3.3 | Cardiac hypertrophy and capillary density

Echocardiographic measurement of LV wall thickness documented that Ang II infusion induced cardiac hypertrophy in both experimental groups. Notably, Ang II–induced increase in wall thickness was more prominent in GILZ-KO hearts. Although in WT mice hypertrophy was demonstrated by 25% increase in LV wall thickness-to-bodyweight ratio, GILZ-KO mice showed an enhanced hypertrophic response with an 80% increase in this parameter (Figure 3A). To evaluate hypertrophic response at the cellular level, cardiomyocyte cross-sectional area was measured in tissue sections after visualization of base membrane with antilamin antibody (Figure 3B). Frequency distribution curve of cardiomyocyte cross-sectional area in GILZ-KO mice was shifted towards bigger values confirming that GILZ-KO favours a more pronounced cardiomyocyte hypertrophic reaction in response to Ang II (Figure 3C). Hypertrophic response is a complex biological process that involves several transcription factors. At this regard, the expression level of GATA4, a critical regulator of hypertrophic process, were investigated. Our findings revealed that FoxP3 transcript and protein were markedly up-regulated after Ang II, and such an increase was less pronounced in GILZ-KO hearts (Figure 3D,E). GATA4 mRNA expression was up-regulated only in Ang II–infused WT mice, whereas it was not modulated in GILZ-KO animals (Figure 3F). Evaluation of capillary density demonstrated a microvascular rarefaction in both Ang II-treated WT and KO animals. Although no statistical differences were observed between WT + Ang and KO + Ang groups, the trend towards a lower capillary density was observed in mice lacking GILZ (KO + Ang: −38%, WT + Ang: −26%; Figure 3G,H). Collectively, these data show that GILZ may play a regulatory role in Ang II–induced cardiomyocyte hypertrophy and confirm that LV hypertrophy can represent the anatomic substrate for diastolic dysfunction.

3.4 | Inflammatory profile

Adverse myocardial remodelling induced by Ang II is not limited to hypertrophy. We have detected significantly modulated cardiac expression of several cytokines, consistent with the pro-inflammatory effects of Ang II.27 Surprisingly, GILZ-KO did not show differences in Ang II–induced myocardial transcripts for TNF-α and IL-1β with the only trend regarding IFN-γ that may indicate higher lymphocyte activity (Figure 4A). Detection of myocardial immune cells by CD45 and CD3 immunolabelling, although clearly demonstrated enhanced infiltration in Ang II–infused mice, did not reveal significant variations between WT and GILZ-KO (Figure 4B). Similarly, nuclear expression of phospho-NF-κBSer536 resulted increased the following Ang II treatment but did not differ WT and GILZ-KO mice (Figure 4C). In order to evaluate the possible activation of NLRP3 inflammasome in our experimental model, the expression of Caspase-1, effector of inflammasome complex, was examined. Our analysis revealed that the active form of Caspase-1 was not present in the heart of untreated and Ang II–treated WT and GILZ-KO mice, excluding the involvement of NLRP3 inflammasome pathway (Figure 4D). To determine whether there were changes in the periphery, spleen lymphocytes were analysed. Cytokine transcripts were unchanged in all four groups, suggesting that in our experimental setting, secondary lymphoid organs were not critically involved (Figure 4E). Overall, these rather unexpected data indicate that, in our model, GILZ does not play a primary role in myocardial inflammatory process that develops upon the excess of Ang II.

3.5 | Myocardial cell death and fibrosis

Myocardial cell death and fibrosis, as well as inflammatory reaction, are hallmarks of adverse remodelling. Apoptotic death measured by TUNEL assay was markedly increased after Ang II, although the rate of apoptosis rose in a comparable manner in WT and KO mice (Figure 5A,B). Similarly, the transcript for pro-apoptotic protein BAX increased after Ang II infusion, but the difference was not statistically significant (Figure 5C). In addition, following Ang II administration, extensive foci of replacement fibrosis were present in the myocardium of both WT and GILZ-KO mice. Damaged areas were composed by the collagen deposits and fibroblasts accumulation (Figure 5D). Moreover, perivascular fibrosis that develops in parallel to focal damage was also evident (Figure 5E). However, we did not observe evident differences in the extent of damage and fibrosis between WT and GILZ-KO hearts. This observation was confirmed by PCR analysis evidencing the overexpression of pro-fibrotic genes, such as TGF-β and its effector CTGF, after Ang II infusion, with no difference between WT and KO mice (Figure 5F).
The principal finding of our study was that the absence of GILZ in response to Ang II–mediated stress resulted in enhanced cardiomyocyte hypertrophy in comparison with WT hearts. In contrast, the increases in myocardial inflammatory and fibrotic reactions were similar between WT and GILZ-KO. Because LV hypertrophy is an undeniable risk factor for HF and sudden death, and represents a valid therapeutic target, this previously unknown role of GILZ in hypertrophic growth can be of interest.38,39

A plethora of effects mediated by Ang II has a well-established place in cardiovascular medicine as both pathogenic component and therapeutic target.40 Ang II, one of the best characterized cardiovascular stressors, is the main effector of the renin-angiotensin system, whose activation leads to hypertension, cell death, cardiac hypertrophy, inflammation, fibrosis, endothelial dysfunction and microvascular rarefaction, all major factors involved in HF pathogenesis.41-43 Of note, increased Ang II–induced hypertrophy in GILZ-KO reported in the present study cannot be attributed to differences in the afterload as in both WT and GILZ-KO, blood pressure was identically
raised. This is consistent with the evidence that Ang II might exert its action on the heart (mainly through Ang II type 1 receptor), promoting fibrotic and hypertrophic pathways independently from arterial pressure changes. Our data suggest that GILZ may be involved in hypertension-independent response to Ang II. Consistently, the importance of GC signalling in cardiovascular diseases has been demonstrated in Cushing’s syndrome, in which GC excess induces adverse structural and functional cardiovascular changes that cannot be explained by the development of hypertension per se.

It is well established that in addition to cardiomyocytes, also other cellular components of myocardium respond to stressors. Adverse remodelling, involving immune cells, cardiac fibroblasts and vascular cells, may manifest as inflammation-driven endothe-

lial dysfunction and fibrosis. In our study, the increased fibro-

blast accumulation and collagen deposit were evident upon Ang II infusion, but neither reactive nor replacement fibrosis was different between WT and GILZ-KO. Although the involvement of GC signalling pathway is plausible because Ang II is among various stimuli of cortisol secretion, and GCs induce angiotensin-converting enzyme and fibroblast activation via TGF-β signalling, the role of GILZ in the response to pro-fibrotic stimulus is unknown. Our findings of a similar fibrotic reaction in WT and KO mice do not indicate a significant involvement of GILZ in a pro-fibrotic re-

sponse to Ang II. Pathological remodelling of the myocardium is characterized not only by an increased extracellular matrix deposition, but also by a loss of cardiomyocytes and other cellular components. Herein, the continuous stress induced by Ang II infusion that mimics a persistent hyperactivity of the renin-angiotensin system together with sustained pressure overload translated into an increased death of myocardial cells. However, in the mice lacking GILZ we did not observe any significant difference in apoptotic rate.

Determinal effects of sterile inflammation on the myocardium are well-recognized despite disappointing clinical results of anti-inflam-

matory approach in HF. Ang II and other stressors stimulate the synthesis of pro-inflammatory cytokines, chemokines and adhesion molecules in the heart and vessels, inducing the recruitment and activa-

tion of T and B lymphocytes, dendritic and natural killer cells. Additionally, GILZ is a known mediator of the immune response, shown to limit inflammation by inhibiting cytokine expression in Th17 immune cells. Herein, Ang II infusion determined an up-regulation of inflammatory genes in the heart, but unexpectedly, GILZ ablation did not affect Ang II-driven development of myocardial infarction. Myocardial CD45+ and CD3+ cells were increased by Ang II at a comparable degree in WT and GILZ-KO. In addition, the activation of NLRP3 inflammasome in this context of sterile inflammation was not detected in the hearts of WT and GILZ-KO mice. These data suggest that the pathways triggered by Ang II in cardiac fibroblasts and immune cells do not critically cross with GILZ. To date, GILZ was studied mainly as a part of an anti-inflammatory effector of GCs, but it may have an impact on myocardial biology given the importance of GC signalling in the heart. Animals with a cardiomyocyte-spe-

cific ablation of GC receptor experience an altered expression of a vast number of cardiac genes and die prematurely, developing LV hypertrophy and dysfunction. Clinically, excess of GCs in Cushing’s syndrome associates with a series of cardiovascular complications, including myocardial fibrosis and hypertrophy. GILZ-KO mice used here did not show spontaneous alteration in cardiac phenotype, but structural and functional abnormalities that became evident after Ang II administration.

Myocardial hypertrophy was the principal component that was at variance in the absence of GILZ that may explain the enhanced deterioration of diastolic function in GILZ-KO hearts. Also, differences in diastolic performance in the presence of a similar extent of fibrosis underline the contribution of cardiomyocyte subcellular changes to LV relaxation and myocardial stiffness. This underlines the regulatory role of GILZ in the response to neurohormonal stress as a potential repressor of cell hypertrophy stimulated by Ang II. This is in line with the evidence that links hypertrophy to GC signalling. The proneness to hypertrophic phenotype in mice lacking GILZ has likely resulted from multifaceted molecular and cellular aspects. A mechanistic hint emerged from the Ang II–induced myocardial expression of transcription factor FoxP3. A relative reduction in FoxP3 level was present in the stressed myocardium of GILZ-KO mice, probably reflecting a regulatory role of GILZ in the expression of FoxP3 in cardiomyocytes. This is consistent with the mechanistic link between FoxP3 and GILZ documented in immune cells. Although the details of molecular interplay of GILZ and FoxP3 in cardiomyocytes remain to be determined, our hypothesis is that the absence of GILZ may condition the expression of FoxP3, leading to excessive hypertrophic response. This is supported by a possible protective role of FoxP3 against the development of cardiac hypertrophy. GILZ ablation was also associated with the differential myocardial expression of GATA4 upon Ang II excess. GATA4 is a key regulator of postnatal heart function and stress-induced hypertrophy of the myocardium. It is implicated in the activation of hypertrophic response in neonatal and adult cardiomyocytes by regulating numerous hypertrophic and differentiation-related genes. In a mouse model of pressure overload, in which a diastolic dysfunction was also observed, higher level of hypertrophic genes correlated with low expression of GATA4, obtained by partial deletion of GATA4 gene. Consistently with these findings, our data showed that a more pronounced hypertrophic response occurred in GILZ-KO mice where low levels of GATA4 were maintained after Ang II infusion. The increase in GATA4 mRNA after Ang II present only in WT mice seems to point to a reg-

ulatory role of GILZ in GATA4 expression, although the question of how the lack of GILZ may affect myocardial level of GATA4 awaits the answer. Several proteins involved in the control of cellular re-

sponse to stress that physically interact with GILZ may also participate in molecular events leading to excessive hypertrophy. In this regard, the role of NF-κB, c-Jun/c-Fos heterodimer, Raf-1, Ras and histone deacetylase 1 needs to be explored.

Because our model consists of a whole-body gene ablation of GILZ, it is very likely that, in addition to cardiomyocytes, other myocardial cells targeted by Ang II are involved. Both in physiolog-

ical and pathological conditions, coronary endothelial cells have a
recognized role as dynamic regulators of surrounding cardiomyocytes, thus affecting their growth and function. In this context, a large body of evidence points to the effects of Ang II and pressure overload on endothelial compartment and angiogenic profile of the myocardium. Our analysis of capillary density revealed a significant rarefaction of coronary microvasculature after Ang II corroborating the hypothesis of the involvement of coronary endothelium.

In conclusion, we report a previously unknown role of GILZ in adverse myocardial remodelling in angiotensin-induced model of cardiac hypertrophy and diastolic dysfunction. The enhanced myocardial response to Ang II in mice lacking GILZ, together with Ang II-induced rise in GILZ expression in wild-type animals, indicates that this protein can be mechanistically involved in cardiovascular pathology. Our data introduce GILZ as a new player in the hypertrophic response of the myocardium, inviting future researches on GILZ as a potential pharmacological target and tool in cardiovascular medicine. This study is to be followed by further work on molecular mechanisms to clarify the role of GILZ signalling in the diseased myocardium.

ACKNOWLEDGEMENTS
This study was supported by PRIN 2015-2015EASE8Z (LB); PON03PE_00060_7 (LB) and PRIN 2017-2017XZMBYX (SB and C.Ra.).

CONFLICTS OF INTEREST
The authors declare no competing or financial interests.

AUTHOR CONTRIBUTION
Donato Cappetta: Conceptualization (equal); Formal analysis (equal); Writing-original draft (equal). Antonella De Angelis: Conceptualization (equal); Supervision (equal). Sara Flamini: Data curation (supporting); Investigation (supporting). Anna Cozzolino: Investigation (supporting). Oxana Bereshchenko: Conceptualization (equal); Data curation (equal); Investigation (equal). Simona Ronchetti: Data curation (equal); Investigation (equal). Eleonora Cianflone: Data curation (supporting); Formal analysis (supporting). Andrea Gagliardi: Data curation (supporting). Erika Ricci: Data curation (supporting). Concetta Rafaniello: Funding acquisition (lead); Investigation (supporting). Francesco Rossi: Supervision (equal); Writing-review & editing (equal). Carlo Riccardi: Supervision (equal); Writing-review & editing (equal). Liberato Berrino: Funding acquisition (equal); Supervision (equal); Writing-review & editing (equal). Stefano Bruscoli: Conceptualization (equal); Data curation (equal); Writing-original draft (equal). Konrad Urbanek: Conceptualization (equal); Data curation (equal); Writing-original draft (equal).

DATA AVAILABILITY STATEMENT
The data sets generated during the current study are available.

ORCID
Antonella De Angelis https://orcid.org/0000-0002-6219-3704

REFERENCES
1. Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in perspective. Circ Res. 2019;124:1598-1617.
2. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32:670-679.
3. Glezeva N, Baugh JA. Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target. Heart Fail Rev. 2014;19:681-694.
4. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodelling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263-271.
5. Ronchetti S, Migliorati G, Bruscoli S, Riccardi C. Defining the role of glucocorticoids in inflammation. Clin Sc (Lond). 2018;132:1529-1543.
6. Giord JP, Brotman DJ. Does altered glucocorticoid homeostasis increase cardiovascular risk? Cardiovasc Res. 2004;64:217-226.
7. Gray GA, White CI, Castellain RF, McSweeney SJ, Chapman KE. Getting to the heart of intracellular glucocorticoid regeneration: 11β-HSD1 in the myocardium. J Mol Endocrinol. 2017;58:R1-R13.
8. Hoppstadtér J, Kessler SM, Bruscoli S, Huwer H, Riccardi C, Kiemer AK. Glucocorticoid-induced leucine zipper: a critical factor in macrophage endotoxin tolerance. J Immunol. 2015;194:6057-6067.
9. Vago JP, Tavares LP, Garcia CC, et al. The role and effects of glucocorticoid-induced leucine zipper in the context of inflammation resolution. J Immunol. 2015;194:4940-4950.
10. Bereshchenko O, Coppo M, Bruscoli S, et al. GLIZ promotes production of peripherally induced Treg cells and mediates the crosstalk between glucocorticoids and TGF-β signaling. Cell Rep. 2014;7:464-475.
11. Bereshchenko O, Migliorati G, Bruscoli S, Riccardi C. Glucocorticoid-induced leucine zipper: a novel anti-inflammatory molecule. Front Pharmacol. 2019;10:308.
12. Bruscoli S, Sorcini D, Flamini S, et al. Glucocorticoid-induced leucine zipper inhibits interferon-gamma production in B cells and suppresses colitis in mice. Front Immunol. 2018;9:1720.
13. Bruscoli S, Biagioli M, Sorcini D, et al. Lack of glucocorticoid-induced leucine zipper (GILZ) deregulates B-cell survival and results in B-cell lymphocytosis in mice. Blood. 2015;126:1790-1801.
14. D’Adamo F, Zollo O, Moraca R, et al. A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death. Immunity. 1997;7:803-812.
15. Di Marco B, Massetti M, Bruscoli S, et al. Glucocorticoid-induced leucine zipper inhibits interferon-gamma production in B cells and suppresses colitis in mice. Front Immunol. 2018;9:1720.
16. Bruscoli S, Biagioli M, Sorcini D, et al. Lack of glucocorticoid-induced leucine zipper (GILZ) deregulates B-cell survival and results in B-cell lymphocytosis in mice. Blood. 2015;126:1790-1801.
17. D’Adamo F, Zollo O, Moraca R, et al. A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death. Immunity. 1997;7:803-812.
18. Di Marco B, Massetti M, Bruscoli S, et al. Glucocorticoid-induced leucine zipper(GILZ)/NF-kappaB interaction: role of GILZ homo-dimerization and C-terminal domain. Nucleic Acids Res. 2007;35:517-528.
19. Ayrodii E, Migliorati G, Bruscoli S, et al. Modulation of T-cell activation by the glucocorticoid-induced leucine zipper factor via inhibition of nuclear factor kappab. Blood. 2001;98:743-753.
20. Ayrodii E, Zollo O, Bastianelli A, et al. GILZ mediates the antiproliferative activity of glucocorticoids by negative regulation of Ras signaling. J Clin Invest. 2007;117:1605-1615.
21. Zhang W, Yang N, Shi XM. Regulation of mesenchymal stem cell osteogenic differentiation by glucocorticoid-induced leucine zipper (GILZ). J Biol Chem. 2008;283:4723-4729.
22. Muller OG, Parnova RG, Centeno G, Rossier BC, Firsov D, Horisberger JD. Mineralocorticoid effects in the kidney: correlation between alphaENaC, GILZ, and Sgk-1 mRNA expression and urinary excretion of Na+ and K+. J Am Soc Nephrol. 2003;14:1107-1115.
23. Shi X, Shi W, Li Q, et al. A glucocorticoid-induced leucine-zipper protein, GILZ, inhibits adipogenesis of mesenchymal cells. EMBO Rep. 2003;4:374-380.
Cappetta ET AL.

21. Cannarile L, Zollo O, D'Adamo F, et al. Cloning, chromosomal as-
    signment and tissue distribution of human GILZ, a glucocorticoid-
    hormone-induced gene. Cell Death Differ. 2001;8:201-203.

22. Bruscoli S, Donato V, Velardi E, et al. Glucocorticoid-induced leu-
    cine zipper (GILZ) and long GILZ inhibit myogenic differentiation
    and mediate anti-inflammatory effects of glucocorticoids. J Biol
    Chem. 2010;285:10385-10396.

23. Rog-Zielinska EA, Craig M-A, Manning JR, et al. Glucocorticoids
    promote structural and functional maturation of foetal cardiomy-
    ocytes: a role for PGC-1α. Cell Death Differ. 2015;22:1106-1116.

24. Aguilard DC, Strom J, Xu B, Kappeler K, Chen QM. Expression of
    glucocorticoid-induced leucine zipper (GILZ) in cardiomyocytes.
    Cardiovasc Toxicol. 2013;13:91-99.

25. Bruscoli S, Velardi E, Di Sante M, et al. Long glucocorticoid-in-
    duced leucine zipper (L-GILZ) protein interacts with ras protein
    pathway and contributes to spermatogenesis control. J Biol
    Chem. 2012;287:1242-1251.

26. Schweng F, Baron U, Rajewsky K. A cre-transgenic mouse strain for
    the ubiquitous deletion of loxP-flanked gene segments including
    deletion in germ cells. Nucleic Acids Res. 1995;23:5080-5081.

27. Matsuda S, Umemoto S, Yoshimura K, et al. Angiotensin II activat-
    es MCP-1 and induces cardiac hypertrophy and dysfunction via toll-
    like receptor 4. J Atheroscler Thromb. 2015;22:833-844.

28. Hernanz R, Martínez-Revelles S, Palacios R, et al. Toll-like receptor 4
    contributes to vascular remodelling and endothelial dysfunction in
    angiotensin II-induced hypertension. Br J Pharmacol. 2015;172:3159-3176.

29. Fan D, Takawale A, Basu R, et al. Differential role of TIMP2 and
    TIMP3 in cardiac hypertrophy, fibrosis, and diastolic dysfunction.
    Cardiovasc Res. 2014;103:268-280.

30. Murdoch CE, Chauhey S, Zeng L, et al. Endothelial NADPH oxi-
    dase-2 promotes interstitial cardiac fibrosis and diastolic dysfunction
    through proinflammatory effects and endothelial-mesenchymal
    transition. J Am Coll Cardiol. 2014;63:2734-2741.

31. Esposito G, Cappetta D, Russo R, et al. Sitagliptin reduces inflam-
    mation, fibrosis and preserves diastolic function in a rat model
    of heart failure with preserved ejection fraction. Br J Pharmacol.
    2017;174:4070-4086.

32. Aquila I, Cianflone E, Scalise M, et al. c-kit Haploinsufficiency im-
    pairs adult cardiac stem cell growth, myogenicity and myocardial
    regeneration. Cell Death Dis. 2019;10:436.

33. Cappetta D, Esposito G, Coppini R, et al. Effects of ranolazine in
    a model of doxorubicin-induced left ventricle diastolic dysfunction.
    Br J Pharmacol. 2017;174:3696-3712.

34. Bai Y, Wang X, Shen L, et al. Mechanical stress regulates endothelial
    progenitor cell angiogenesis through VEGF receptor endocytosis.
    Int Heart J. 2019;10:436.

35. Cappetta D, Ciuffreda LP, Cozzolino A, et al. Dipeptidyl pep-
    tidase 4 inhibition ameliorates chronic kidney disease in a
    model of salt-dependent hypertension. Oxid Med Cell Longev.
    2019;2019:8912768.

36. De Angelis A, Cappetta D, Piegari E, et al. Long-term administration
    of heart failure with preserved ejection fraction. Int J Cardiol.
    2016;217:69-79.

37. Sadoshima J. Cytokine actions of angiotensin II. Circ Res.
    2000;86:1187-1189.

38. Heinzl FR, Hohendanner F, Jin G, Sedej S, Edelmann F. Myocardial
    hypertrophy and its role in heart failure with preserved ejection
    fraction. J Appl Physiol. 2015;119(10):1233-1242.

39. Stevens SM, Reinier K, Chugh SS. Increased left ventricular mass as
    a predictor of sudden cardiac death: is it time to put it to the test?
    Circ Arrhythm Electrophysiol. 2013;6:212-217.

40. Ferrario CM. Role of angiotensin II in cardiovascular disease ther-
    apeutic implications of more than a century of research. J Renin
    Angiotensin Aldosterone Syst. 2006;7:3-14.

41. Forrester SJ, Booz GW, Sigmund CD, et al. Angiotensin II signal
    transduction: an update on mechanisms of physiology and patho-
    physiology. Physiol Rev. 2018;98:1627-1738.

42. Tomak J, Bub G. Hypertension-induced remodelling: on the interac-
    tions of cardiac risk factors. J Physiol. 2017;595:4027-4036.

43. Gomolak JR, Didion SP. Angiotensin II-induced endothelial dysfunc-
    tion is temporally linked with increases in interleukin-6 and vascular
    macrophage accumulation. Front Physiol. 2014;5:396.

44. Tokuda K, Kai H, Kuwahara F, et al. Pressure-independent effects
    of angiotensin II on hypertensive myocardial fibrosis. Hypertension.
    2004;43:499-503.

45. Avenatti E, Rebellato A, Iannaccone A, et al. Left ventricular ge-
    ometry and 24-h blood pressure profile in Cushing’s syndrome.
    Endocrine. 2017;55:547-554.

46. Sutahar N, Meijers WC, Sillijé HHW, de Boer RA. From inflamma-
    tion to fibrosis-molecular and cellular mechanisms of myocardial
    tissue remodelling and perspectives on differential treatment op-
    portunities. Curr Heart Fail Rep. 2017;14:235-250.

47. Rábano M, Peña A, Brizuela L, Macarulla JM, Gómez-Muñoz A,
    Trueba M, Angiotensin II-stimulated cortisol secretion is mediated
    by phospholipase D. Mol Cell Endocrinol. 2004;222:9-20.

48. Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: new
    roles in inflammation, immunology and aging. EMBO Mol Med.
    2010;2:247-257.

49. Rinaldi B, Pieri L, Donnacuo M, et al. Rosiglitazone reduces the
    inflammatory response in a model of vascular injury in rats. Shock.
    2009;32:638-644.

50. Yosef N, Shalek AK, Gaudelomme JT, et al. Dynamic regulatory net-
    work controlling Th17 cell differentiation. Nature. 2013;496:461-468.

51. Oakley RH, Ren R, Cruz-Topete D, et al. Essential role of stress hor-
    mone signaling in cardiomyocytes for the prevention of heart dis-
    ease. Proc Natl Acad Sci USA. 2013;110:17035-17040.

52. De Leo M, Pivonello R, Auriemma RS, et al. Cardiovascular disease in
    Cushing’s syndrome: heart versus vasculature. Neuroendo-
    crinology. 2010;9(Suppl 1):50-54.

53. Matsuhashi T, Endo J, Katsumata Y, et al. Pressure overload inhibits
    glucocorticoid receptor transcriptional activity in cardiomyocytes
    and promotes pathological cardiac hypertrophy. J Mol Cell Cardiol.
    2019;130:122-130.

54. Chen QM, Alexander D, Sun H, et al. Corticosteroids inhibit cell
    death induced by doxorubicin in cardiomyocytes: induction of an-
    tiapoptosis, antioxidant, and detoxification genes. Mol Pharmacol.
    2005;67:1861-1873.

55. Ding YY, Li JM, Guo FJ, et al. Triptolide upregulates myocardial fork-
    head helix transcription factor p3 expression and attenuates car-
    diac hypertrophy. Front Pharmacol. 2016;7:471.

56. Oka T, Maillet M, Watt AJ, et al. Cardiac-specific deletion of Gata4
    reveals its requirement for hypertrophy, compensation, and myo-
    cyte viability. Circ Res. 2006;98:837-845.

57. Liang Q, De Windt LJ, Witt SA, Kimball TR, Markham BE,
    Molkentin JD. The transcription factors GATA4 and GATA6 regu-
    late cardiomyocyte hypertrophy in vitro and in vivo. J Biol Chem.
    2007;282:30245-30253.

58. Cianflone E, Aquila I, Scalise M, et al. Molecular basis of functional
    myogenic specification of Bona Fide multipotent adult cardiac stem
    cells. Cell Cycle. 2018;17:927-946.

59. Marino F, Scalise M, Cianflone E, et al. Role of c-kit in myocardial
    regeneration and aging. Front Endocrinol. 2019;10:371.

60. Scalise M, Torella M, Marino F, et al. Atrial myxomas arise from mul-
    tipotent cardiac stem cells. Eur Heart J. 2020;ehaa156. https://doi.
    org/10.1093/eurheartj/ehaa156. [Epub ahead of print].

61. Bispeng I, Ikeda S, Kong SW, et al. Gata4 is required for mainte-
    nance of postnatal cardiac function and protection from pres-
    sure overload-induced heart failure. Proc Natl Acad Sci USA.
    2006;103:14471-14476.
62. Cappetta D, De Angelis A, Ciuffreda LP, et al. Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium. *Pharmacol Res*. 2020;157:104781.

63. Liu X, Wu J, Zhu C, et al. Endothelial S1pr1 regulates pressure overload-induced cardiac remodelling through AKT-eNOS pathway. *J Cell Mol Med*. 2020;24:2013-2026.

64. Dushpanova A, Agostini S, Ciofini E, et al. Gene silencing of endothelial von Willebrand factor attenuates angiotensin II-induced endothelin-1 expression in porcine aortic endothelial cells. *Sci Rep*. 2016;6:30048.

65. Brutsaert DL. Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. *Physiol Rev*. 2003;83:59-115.

66. Zoja C, Cattaneo S, Fiordaliso F, et al. Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes. *Am J Physiol Renal Physiol*. 2011;301:F1114-F1123.

How to cite this article: Cappetta D, De Angelis A, Flamini S, et al. Deficit of glucocorticoid-induced leucine zipper amplifies angiotensin-induced cardiomyocyte hypertrophy and diastolic dysfunction. *J Cell Mol Med*. 2021;25:217–228. [https://doi.org/10.1111/jcmm.15913](https://doi.org/10.1111/jcmm.15913)